Vascular endothelial growth factor serum concentrations in hypercholesterolemic patients

References

• Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol 1999; 237: 1–30
   PubMed Web of Science ®Google Scholar
• Harada M., Mitsuyama K., Yoshida H., Sakisaka S., Taniguchi E., Kawaguchi T., et al. Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumatol 1998; 27: 377–80
   PubMed Web of Science ®Google Scholar
• Kearney T. M., Witzenbichler B., Chen D., Murohara T., Losordo D. W., Symes J., et al. Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries. Am J Pathol 1997; 150: 1673–85
   PubMed Web of Science ®Google Scholar
• Inoue M., Itoh H., Ueda M., Naruko T., Kojima A., Komatsu R., et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 1998; 98: 2108–16
   PubMed Web of Science ®Google Scholar
• Barleon B., Sozzani S., Zhou D. Wiech HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor fit‐1. Blood 1996; 87: 3336–43
   PubMed Web of Science ®Google Scholar
• Grosskreutz C. L., Anand‐Apte B., Duplaa C., Quinn T. P., Terman B. I., Zetter B., et al. Vascular endothelial growth factor induced migration of vascular smooth muscle cells in vitro. Microvasc Res 1999; 58: 128–36
   PubMed Web of Science ®Google Scholar
• Wang H., Keiser J. A. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of fit‐1. Circ Res 1998; 83: 832–40
   PubMed Web of Science ®Google Scholar
• Rak J., Mitsuhashi Y., Bayko L., Filmus J., Shirasawa S., Sasazuki T., et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995; 55: 4575–80
   PubMed Web of Science ®Google Scholar
• Ramos M. A., Kuzuya M., Esaki T., Miura S., Satake S., Asai T., et al. Induction of macrophage VEGF in response to oxidized LDL and VEGF accumulation in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1998; 18: 1188–96
   PubMed Web of Science ®Google Scholar
• Guijarro C., Blanco‐Colio L. M., Ortego M., Alonso C., Ortiz A., Plaza J. J., et al. 3‐Hydroxy‐3‐methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998; 83: 490–500
   PubMed Web of Science ®Google Scholar
• Casey P. J., Solski P. A., Der C. J., Buss J. E. p21ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci USA 1989; 86: 8323–7
   PubMed Web of Science ®Google Scholar
• Rosenson R. S., Tangney C. C., Casey L. C. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999; 353: 983–4
   PubMed Web of Science ®Google Scholar
• Inoue I., Goto S., Mizotani K., Awata T., Mastunaga T., Kawai S., et al. Lipophilic HMC‐CoA reductase inhibitor has an anti‐inflammatory effect: reduction of mRNA levels for interleukin‐1beta, interleukin‐6, cyclooxygenase‐2 and p22phox by regulation of peroxisome proliferator‐activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci 2000; 67: 863–76
   PubMed Web of Science ®Google Scholar
• Ridker P. M., Rifai N., Pfeffer M. A., Sacks F., Braumwald E. Long‐term effects of pravastatin on plasma concentration of C‐reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230–5
   PubMed Web of Science ®Google Scholar
• Hoffamn R., Brook GJ Aviram M. Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies. Atherosclerosis 1992; 93: 105–13
   PubMed Web of Science ®Google Scholar
• Blann A. D., Belgore F. M., Constans J., Conri C., Lip G. Y. Plasma vascular endothelial growth factor and its receptor Fit‐1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. Am J Cardiol 2001; 87: 1160–3
   PubMed Web of Science ®Google Scholar
• Celletti F. L., Waugh J. M., Amabile P. G., Brendolan A., Hilfiker P. R., Dake M. D. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nature Med 2001; 7: 425–9
   PubMed Web of Science ®Google Scholar
• Mellies M. J., Devault A. R., Kassier‐Taub K., McGovern M. E., Pan H. Y. Pravastatin experience in elderly and non‐elderly patients. Atherosclerosis 1993; 101: 97–101
   PubMed Web of Science ®Google Scholar
• Grip O., Janciauskiene S., Lindgren S. Pravastatin down‐regulates inflammatory mediators in human monocytes in vitro. Eur J Pharmacol 2000; 410: 83–92
   PubMed Web of Science ®Google Scholar
• Ferro D., Parrotto S., Basili S., Alessandri C., Violi F. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 2000; 36: 427–31
   PubMed Web of Science ®Google Scholar
• Musial J., Undas A., Gajewski P., Jankowski M., Sydor W., Szczeklik A. Anti‐inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol 2001; 77: 247–53
   PubMed Web of Science ®Google Scholar
• Hojo Y., Ikeda U., Maeda Y., Takahashi M., Takizawa T., Okada M., et al. Interaction between human monocytes and vascular smooth muscle cells induces vascular endothelial growth factor expression. Atherosclerosis 2000; 150: 63–70
   PubMed Web of Science ®Google Scholar
• Inouse M., Itoh H., Tanaka T., Chun T. H., Doi K., Fukunaga Y., et al. Oxidized LDL regulates vascular endothelial growth factor expression in human macrophages and endothelial cells through activation of peroxisome proliferator –activated receptor‐gamma. Arterioscler Thromb Vasc Biol 2001; 21: 560–6
   PubMed Web of Science ®Google Scholar
• Girona J., La Ville A. E., Sola R., Motta C., Masana L. Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am J Cardiol 1999; 83: 846–51
   PubMed Web of Science ®Google Scholar
• Sakai M., Kobori S., Matsumura T., Biwa T., Sato Y., Takemura T., et al. HMG‐CoA reductase inhibitors suppress macrophage growth by oxidized low‐density lipoprotein. Atherosclerosis 1997; 133: 51–9
   PubMed Web of Science ®Google Scholar